Amit Bar-Or
Neurology · Philadelphia, PANPI 1528508843
Payments from drug & device makers
Across 395 payments — averaging $19,570 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2.7M
- Novartis Pharma AG$1.9M
- Genentech, Inc.$1.9M
- F. Hoffmann-la Roche AG$413K
- Biogen$279K
- Sanofi$260K
- plus $260K from 19 others
Across 145 payments — averaging $1040.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$88K
- Novartis$45K
- Sanofi$7K
- Bristol Myers Squibb$7K
- Novartis Pharma AG$2K
- Genentech, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $2,740,046 |
| Novartis Pharma AG | 27 | $1,915,667 |
| Genentech, Inc. | 68 | $1,861,620 |
| F. Hoffmann-la Roche AG | 68 | $413,423 |
| Biogen | 13 | $278,604 |
| Sanofi | 71 | $260,384 |
| EMD Serono, Inc. | 46 | $68,390 |
| Sanofi-aventis U.S. LLC | 12 | $48,637 |
| Sanofi US Services Inc. | 9 | $32,047 |
| Hoffmann-la Roche Limited | 9 | $24,431 |
| GSK | 16 | $16,896 |
| Bristol Myers Squibb | 9 | $13,427 |
| Roche Products Limited | 10 | $9,977 |
| Modernatx, Inc. | 2 | $6,800 |
| Teva Pharmaceuticals USA, Inc. | 2 | $6,080 |
| Merck Serono S.p.a. | 1 | $5,895 |
| Shionogi Inc | 2 | $5,135 |
| Merck Kgaa | 1 | $4,240 |
| Amgen | 1 | $4,200 |
| AstraZeneca(2 entities) | 3 | $3,450 |
| Merck | 1 | $3,390 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,200 |
| Janssen Global Services, LLC | 1 | $3,100 |
| Eli Lilly | 7 | $847 |
| Genentech USA, Inc. | 3 | $106 |
How this compares
$7,729,991 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Philadelphia
- Thomas LeistPhiladelphia$5.8M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
- Andres Deik Acosta MadiedoPhiladelphia$1.8M
- Michael SperlingPhiladelphia$1.7M
- Sanjeev VaishnaviPhiladelphia$1.6M
- Andrew SiderowfPhiladelphia$1.4M
- Sami KhellaPhiladelphia$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.